Related Experiment Video
Updated: Nov 2, 2025
Magnetic Isolation of Microglial Cells from Neonate Mouse for Primary Cell Cultures
Published on: July 25, 2022
Edaravone Plays Protective Effects on LPS-Induced Microglia by Switching M1/M2 Phenotypes and Regulating NLRP3
Jiping Li1, Xinping Dai2, Liuyi Zhou3
1Department of Neurosurgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Abstract:
Parkinson's disease is a neurodegenerative disorder in which activated microglia may appear prior to motor symptoms, but the specific therapeutic mechanisms remain unclear. This study investigated the potential effects of Edaravone (EDA) on M1/M2 polarization of microglia in rats with dopaminergic neurons damage induced by lipopolysaccharide (LPS) and its mechanism. Rats were randomly grouped as the following (n = 10): Control, EDA alone (10 mg/kg), LPS-model (LPS 5 μg), LPS + EDA (5 mg/kg) and LPS + EDA (10 mg/kg). After intragastric administration of EDA once a day for seven consecutive days, LPS was injected into SN pars unilaterally. Rotarod test, pole test, and traction test were used to analyze the intervention effect of EDA on neurobehavioral function in rats. Protein expression levels of TH, TNF-α, Arg-1, Iba-1, NLRP3 and caspase-1 were measured by immunofluorescence staining and western blot. In vitro, BV-2 cells were treated with LPS (100 ng/ml) before adding different doses of EDA. Levels of inflammatory cytokines in culture medium were detected by ELISA. Western blot and immunofluorescence were used to evaluate microglial activation and polarization. First, rotarod test, pole test, and traction test all showed that EDA mitigated motor dysfunction of PD rats. Second, pathological analysis suggested that EDA inhibited LPS-induced microglial activation and remitted declines of dopaminergic neurons. In addition, EDA shifted M1 pro-inflammatory phenotype of microglia to M2 anti-inflammatory state, while decreased expression of M1 markers (TNF-α and IL-1β) and facilitated expression of M2 markers (Arg-1 and IL-10). EDA suppressed inflammatory responses through inhibiting the expression of pro-inflammatory factors (IL-1β, IL-18 and NO), but the neuroprotective effects were invalid while siRNA NLRP3 existed. In conclusion, these results indicated that EDA could improve neurobehavioral functions and play anti-neuroinflammatory roles in PD rats, possibly by inhibiting NLPR3 inflammasome activation and regulating microglia M1/M2 polarization.
Insights
Edaravone (EDA) improves motor function in Parkinson's disease (PD) rats by reducing neuroinflammation. It shifts microglia from a pro-inflammatory M1 state to an anti-inflammatory M2 state, potentially by inhibiting NLRP3 inflammasome activation.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms and dopaminergic neuron loss.
- Microglial activation, particularly the M1 pro-inflammatory phenotype, is implicated in PD pathogenesis, but therapeutic mechanisms require clarification.
- Edaravone (EDA) is an antioxidant with potential anti-inflammatory properties.
Purpose of the Study:
- To investigate the effects of Edaravone (EDA) on microglial polarization (M1/M2) in a rat model of Parkinson's disease (PD).
- To elucidate the underlying mechanisms of EDA's potential therapeutic effects in PD, focusing on neuroinflammation and dopaminergic neuron protection.
Main Methods:
- Establishment of a PD rat model using lipopolysaccharide (LPS) injection to induce dopaminergic neuron damage.
- Administration of varying doses of Edaravone (EDA) to assess its impact on neurobehavioral function (Rotarod, pole, traction tests).
- Evaluation of microglial activation and polarization (M1/M2 markers like TNF-α, Arg-1, Iba-1) and dopaminergic neuron survival (TH) using immunofluorescence and Western blot. In vitro studies used BV-2 cells and ELISA for cytokine analysis.
Main Results:
- Edaravone (EDA) significantly improved motor dysfunction in PD rats.
- EDA treatment inhibited LPS-induced microglial activation and protected dopaminergic neurons.
- EDA shifted microglia from the M1 pro-inflammatory to the M2 anti-inflammatory phenotype, decreasing M1 markers (TNF-α, IL-1β) and increasing M2 markers (Arg-1, IL-10).
- EDA suppressed inflammatory responses by inhibiting NLRP3 inflammasome activation, as neuroprotection was lost with NLRP3 knockdown.
Conclusions:
- Edaravone (EDA) demonstrates neuroprotective and anti-neuroinflammatory effects in a rat model of Parkinson's disease (PD).
- EDA's therapeutic benefits are associated with the regulation of microglial M1/M2 polarization towards an anti-inflammatory M2 phenotype.
- Inhibition of the NLRP3 inflammasome pathway is a key mechanism underlying Edaravone's (EDA) efficacy in PD treatment.
